The Thesis
Insulet is a medical device business that earns money by selling wearable, tubeless insulin pumps for people living with diabetes. The company generated $2.71 billion in revenue last year, a 31% increase over the previous year, while expanding its reach to hundreds of thousands of users. The ongoing expansion into the massive Type 2 diabetes market marks the structural shift that makes the next phase of growth possible.
What makes this work boils down to a few specific things.
In our view, there is meaningful upside still ahead, driven by how effectively Insulet is capturing the massive and underserved Type 2 diabetes market. The case for owning the stock strengthens as the company proves it can maintain high margins while scaling globally. We think the current price does not fully reflect the potential for Insulet to become the dominant platform for all insulin delivery. For long-term investors, Insulet offers a clear path to sustained growth in a critical healthcare niche.
Numbers at a Glance
What does it do?
Insulet is a growth business that earns money by selling disposable, tubeless insulin pumps that automate insulin delivery for people with diabetes. The core product, Omnipod, is a self-adhesive "pod" that a patient wears on their skin for three days. Unlike traditional pumps, it has no tubes to catch on clothing or interfere with daily life. Patients pay for a starter kit and then purchase ongoing supplies of disposable pods, creating a recurring revenue stream. The system integrates with continuous glucose monitors to automatically adjust insulin levels, which significantly improves health outcomes for users.
Where does revenue come from?
The vast majority of revenue comes from selling Omnipod devices to patients through both pharmacy and wholesale channels. Most of this revenue is recurring because each pod only lasts 72 hours, requiring customers to buy a constant supply of new ones. A small portion of revenue comes from a drug delivery segment where Insulet partners with pharmaceutical companies to use its pod technology for other injectable drugs. Geographically, about 68% of revenue is generated in the United States, with the remaining 32% coming from a rapidly growing international business.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Insulet serves a growing global community of hundreds of thousands of patients with Type 1 and Type 2 diabetes who require daily insulin. The company recently reported $761.7 million in quarterly revenue, driven by a 36.9% increase in Omnipod sales. The user base is expanding quickly into the Type 2 market, where millions of people still rely on multiple daily injections. Insulet also interacts with healthcare providers who prescribe the device and insurance companies that provide coverage for the monthly pod supplies.
What gives it staying power?
High switching costs protect the business because once a patient is trained on the Omnipod system and its automation software, they are unlikely to leave. The tubeless form factor is a unique physical advantage that traditional competitors cannot easily replicate. Patents on the pod design and integrated software algorithms create a further barrier for new entrants.
Where is it headed?
The single biggest strategic bet Insulet is making is the full-scale entry into the Type 2 diabetes market. Management is currently conducting pivotal clinical trials to secure regulatory approval for an automated insulin delivery system specifically for Type 2 patients. This market is several times larger than the Type 1 market where Insulet currently dominates. If this works, it could triple the company's addressable user base over the next decade.
The revenue trend is accelerating as the company successfully moves into the pharmacy channel where adoption is easier and faster. Revenue grew 33.9% in the most recent quarter, reaching $761.7 million. This growth is being driven by the rapid adoption of the Omnipod 5 system across both U.S. and international markets.
Free cash flow is consistently positive and growing, proving that Insulet can fund its own expansion without taking on excessive debt. The company generated $0.38 billion in free cash flow last year, which is a high-quality result for a business growing at this pace. This cash is being reinvested into new manufacturing facilities to support the projected volume of billions of pods.
The balance sheet is in a strong position with a manageable debt-to-equity ratio of 0.73x and growing cash reserves. Insulet is using its financial strength to buy back shares, including $235 million in repurchases during the last quarter. This flexibility allows the company to invest in research and development while returning value to shareholders.
Insulet is a financially robust business with high margins and a self-funding growth model that is rare in the medical device sector.
The international business is growing much faster than the domestic market, with Omnipod revenue up 59.4% outside the U.S. last quarter. This proves that the tubeless patch pump has global appeal and can navigate diverse healthcare reimbursement systems. The launch in 19 countries so far shows a clear path to continued geographic expansion.
The competitive threat from integrated competitors like Tandem and Medtronic remains the primary risk to watch. While Insulet has the only tubeless option, competitors are working on their own patch pumps to challenge this niche. If a competitor launches a tubeless device with superior software, Insulet's pricing power and market share could come under pressure.
The global insulin pump market is roughly $5 billion today and is growing at ~15% annually as patients move away from manual injections. This market is on track to exceed $10 billion by 2030. It is a high-quality industry because patients rarely switch devices once they start, giving established players structural pricing power. Insulet is the undisputed leader in the tubeless segment, which is the fastest-growing part of the entire market.
The competitive dynamic is characterized by high barriers to entry due to strict regulatory requirements and complex manufacturing. This creates a rational market where a few large players compete on technology rather than just price. Pricing power is high because insurance companies prefer the pharmacy-based model that Insulet pioneered.
Tandem is the most direct threat as they move from tubed pumps into the tubeless patch market. Medtronic(MDT) remains a formidable opponent because they can bundle pumps with their own continuous glucose sensors. The entry of large diversified medical companies into the patch pump space is the single most dangerous threat to Insulet's dominance.
Insulet is currently gaining share as the only company offering a fully automated, tubeless system in the pharmacy channel. Total Omnipod revenue grew 36.9% last quarter, which is significantly faster than the overall market. Insulet is consolidating its lead as the preferred choice for new insulin pump users.
The primary source of protection is high switching costs that exist because patients must be trained on a specific device and its unique software. Once a user integrates the Omnipod 5 into their daily routine, the friction of switching to a competitor is very high. The tubeless form factor is protected by a deep portfolio of patents that prevent rivals from simply copying the design.
The 71% gross margin and 16.4% ROIC prove that Insulet has real pricing power and capital efficiency. These numbers are consistent with a business that has a narrow but durable moat. The recurring revenue from disposable pods creates a financial floor that competitors find difficult to disrupt.
The moat is strengthening as Insulet integrates its software with more sensor brands like Dexcom and Abbott. This software ecosystem makes the device stickier for users and harder for competitors to displace.
Revenue grew 33.9% last quarter, exceeding the high end of guidance.
Repurchased 1.25 million shares last quarter while funding a new manufacturing facility.
CEO compensation is tied to constant currency revenue growth and operating margin expansion.
Capital Allocation Track Record
Management has delivered consistent results by focusing on the tubeless niche and expanding into the pharmacy channel. The team has proven it can scale manufacturing while increasing operating margins by 110 basis points in a single year. Their decision to aggressively pursue the Type 2 market through clinical trials shows a clear and disciplined path to long-term value creation.
© 2026 ClearThesis.ai · Report generated on May 27, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.